Jacques D Nguyen1,2, Yanabel Grant1,2, Michael A Taffe1,2. 1. Department of Neuroscience, The Scripps Research Institute, La Jolla, California, USA. 2. Department of Psychiatry, University of California San Diego, La Jolla, California, USA.
Abstract
BACKGROUND AND PURPOSE: The extra medical use of, and addiction to, prescription opioid analgesics is a growing health problem. To characterize how prescription opioid abuse develops, this study investigated the affective consequences of escalating prescription opioid use using intracranial self-stimulation (ICSS) reward and oxycodone intravenous self-administration (IVSA) models. EXPERIMENTAL APPROACH: Male Wistar rats were given access to oxycodone IVSA (0.15 mg·kg-1 per infusion, i.v.) in short-access (ShA; 1 h) or long-access (LgA; 12 h) sessions for five sessions per week followed by intermittent 60-h discontinuations from drug access, a novel explicit test of the negative reinforcement hypothesis. Separate groups were first trained in the ICSS procedure and then in oxycodone IVSA in 11-h LgA sessions. KEY RESULTS: Rats given LgA to oxycodone escalated their responding more than ShA rats, with further significant increases observed following each 60-h discontinuation. Presession brain reward thresholds increased with sequential daily LgA IVSA sessions, consistent with a growing negative affective state consequent to successive daily intoxication/abstinence cycles. A 1-h oxycodone IVSA interval was sufficient to normalize these elevated reward thresholds, as was, paradoxically, a 60-h weekend abstinence. The increase in ICSS thresholds was attenuated in a group treated with the long-acting κ-opioid antagonist norbinaltorphimine prior to IVSA training. CONCLUSION AND IMPLICATIONS: Changes in brain reward function during escalation of oxycodone self-administration are driven by an interplay between κ-opioid receptor-mediated negative affective state associated with escalated oxycodone intake and dynamic restoration of brain reward status during longer periods of abstinence.
BACKGROUND AND PURPOSE: The extra medical use of, and addiction to, prescription opioid analgesics is a growing health problem. To characterize how prescription opioid abuse develops, this study investigated the affective consequences of escalating prescription opioid use using intracranial self-stimulation (ICSS) reward and oxycodone intravenous self-administration (IVSA) models. EXPERIMENTAL APPROACH: Male Wistar rats were given access to oxycodone IVSA (0.15 mg·kg-1 per infusion, i.v.) in short-access (ShA; 1 h) or long-access (LgA; 12 h) sessions for five sessions per week followed by intermittent 60-h discontinuations from drug access, a novel explicit test of the negative reinforcement hypothesis. Separate groups were first trained in the ICSS procedure and then in oxycodone IVSA in 11-h LgA sessions. KEY RESULTS: Rats given LgA to oxycodone escalated their responding more than ShA rats, with further significant increases observed following each 60-h discontinuation. Presession brain reward thresholds increased with sequential daily LgA IVSA sessions, consistent with a growing negative affective state consequent to successive daily intoxication/abstinence cycles. A 1-h oxycodone IVSA interval was sufficient to normalize these elevated reward thresholds, as was, paradoxically, a 60-h weekend abstinence. The increase in ICSS thresholds was attenuated in a group treated with the long-acting κ-opioid antagonist norbinaltorphimine prior to IVSA training. CONCLUSION AND IMPLICATIONS: Changes in brain reward function during escalation of oxycodone self-administration are driven by an interplay between κ-opioid receptor-mediated negative affective state associated with escalated oxycodone intake and dynamic restoration of brain reward status during longer periods of abstinence.
Authors: Carrie L Wade; Leandro F Vendruscolo; Joel E Schlosburg; Daniel O Hernandez; George F Koob Journal: Neuropsychopharmacology Date: 2014-07-25 Impact factor: 7.853
Authors: Joel E Schlosburg; Timothy W Whitfield; Paula E Park; Elena F Crawford; Olivier George; Leandro F Vendruscolo; George F Koob Journal: J Neurosci Date: 2013-12-04 Impact factor: 6.167
Authors: S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice Journal: Psychopharmacology (Berl) Date: 2010-01-26 Impact factor: 4.530
Authors: Caroline B Pantazis; Luis A Gonzalez; Brendan J Tunstall; Stephanie A Carmack; George F Koob; Leandro F Vendruscolo Journal: Sci Adv Date: 2021-04-07 Impact factor: 14.136
Authors: Sophia Khom; Jacques D Nguyen; Sophia A Vandewater; Yanabel Grant; Marisa Roberto; Michael A Taffe Journal: Front Behav Neurosci Date: 2021-12-16 Impact factor: 3.617